BioSpace News Archive

Labcorp announced the U.S. Food and Drug Administration has granted Emergency Use Authorization for its Mpox PCR Test Home Collection Kit to aid in the diagnosis of infection with non-variola Orthopoxvirus, including the monkeypox virus that causes monkeypox, also known as mpox.

Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA), a clinical-stage immunotherapy company focused on the development of Superkines, presented updated clinical results from the monotherapy dose escalation and ongoing expansion portions of the Phase 1/2 ABILITY-1 (ABeta-only IL-2 ImmunoTherapY) study.

Crescendo Biologics Ltd has presented preclinical data at the 2024 American Association for Cancer Research Annual Meeting on its two leading programmes.

BioXcel Therapeutics, Inc. announced details regarding the planned design of its upcoming TRANQUILITY In-Care Phase 3 trial to evaluate BXCL501, the company’s investigational proprietary, orally dissolving film formulation of dexmedetomidine, as a potential acute treatment for agitation associated with Alzheimer’s dementia in the care setting.

Apollomics Inc., a clinical-stage biopharmaceutical company developing medicines to address difficult-to-treat cancers, presented two posters at the 2024 American Association for Cancer Research Annual Meeting, held April 5-10, 2024 in San Diego, Calif.

HOOKIPA Pharma Inc. announced that members of HOOKIPA’s Executive Team will host an investor call summarizing the Company’s constructive regulatory interactions with the U.S. Food & Drug Administration and the European Medicines Agency.

TORL BioTherapeutics, LLC, is a clinical-stage biotechnology company involved in discovery and development of new antibody-based immunotherapies designed to improve and extend the lives of patients with cancer worldwide.

Scinai Immunotherapeutics Ltd. announced that the company’s Chief Science Officer, Dr. Tamar Ben-Yedidia, and the University Medical Center Göttingen’s Director, Department of Dermatology, Venereology & Allergology, Prof. Michael Schön, will be presenting together at the upcoming 5th Dermatology Drug Development Summit Europe, which will take place in Berlin between April 16-18, 2024.

Ginkgo Bioworks today announced that it has been awarded a grant from the Bill & Melinda Gates Foundation to build an open-access, AI-enabled measles forecasting model to empower proactive public health measures, such as immunization campaigns, in partnership with Northeastern University researchers Alessandro Vespignani and Sam Scarpino.

Castle Biosciences, Inc. today announced that, for the second year in a row, its chief financial officer, Frank Stokes, has been selected as a Top 25 CFO of Houston by TOP CFOs (formerly Finance & Investing).